Navigation Links
Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
Date:11/11/2009

BROOMFIELD, Colo., Nov. 11 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at Lazard Capital Markets 6th Annual Healthcare Conference November 17-18, 2009 at the St. Regis Hotel in New York.

Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Tuesday, November 17 at 4:10 p.m. EST. A breakout session will follow Dr. Orndorff's presentation where he will be available for questions and answers.

About Axona(TM)

Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.

Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharma
'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
2. CryoLife to Present at Upcoming Investor Conferences in New York
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
5. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. VIVUS to Present at Lazard Capital Markets Healthcare Conference
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Thoratec Presentation at Canaccord Adams Conference to be Webcast
9. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
10. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
11. Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Inferior Vena Cava (IVC) Filters - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is projected to reach US$435 million by 2016. The ... 39% (2015) of the global value while ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... begin Phase IIb study in the first half of ... (Nasdaq: ALSE ), announced today that it has,concluded ... in acute,spinal cord injury (SCI). A total of 48 ... States and Canada. We expect to release periodic,updates of ...
... PHILLIPSBURG, N.J., Jan. 7 Celldex Therapeutics,announced today ... has,granted Fast Track designation to Celldex,s CDX-110 for ... is the most common,and aggressive form of primary ... current therapy. CDX-110 is an immunotherapy that targets,the ...
Cached Medicine Technology:Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 5Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 3Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 4Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 5
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... in America, and work commitment is a big reason why, ... killer," said Dr. Mathias Basner, an assistant professor of sleep ... School of Medicine. A time-use survey of nearly 125,000 ... the main activity exchanged for sleep. Short sleepers -- those ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... Health Dialog, a leading provider ... it has received Patient Oriented Accreditation from the ... Disease Management (DM) Programs for asthma, congestive heart ... disease and diabetes. This marks the 12th continuous ... Disease Management (DM) Programs, reaffirming Health Dialog’s focus ...
(Date:12/15/2014)... 15, 2014 Kathy McAfee, America's Marketing ... World Awards in the category of Best Blog 2014. ... for her weekly career blog Networking Ahead ... help professionals elevate their talent and influence through better ... after her book Networking Ahead for Business, has been ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for ... prevalent than coliforms, it cannot reproduce in the presence of ... Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the environment ... Maintain the same sampling method with results as quick ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... Care Hero Award Winners Saluted at Kickoff Event , ... today celebrated Health Careers Week in Pennsylvania by urging ... 10 in-demand allied health occupations. , "There will ... the state over the next seven years," said Governor ...
... ROCHESTER, Minn., Nov. 10 New Mayo Clinic research studied ... and found that routine annual evaluation of prostate growth is ... However the study suggests that if a man,s PSA level ... if he has prostate cancer. These findings are being presented ...
... roles often take the place of a partnership, researchers ... many wedding vows include the phrase "in sickness and ... the test by causing major relationship problems for married ... Ulster study included 16 married stroke survivors (nine males, ...
... ... and consistent alternative to chicken lysozyme, which is used in bacterial cell lysis. Tests ... protein yield from bacterial fermentation. , ... Fort Collins, CO (PRWEB) November 10, 2009 -- Manufactured in an ...
... YORK, Nov. 10 Reportlinker.com announces that a ... catalogue. , US World Nutraceutical Ingredients ... , Global demand to advance 6.2% ... nutraceutical ingredients worldwide is projected to advance 6.2 ...
... 10 Reportlinker.com announces that a new ... catalogue. , Ophthalmology and Optometry ... http://www.reportlinker.com/p0161962/Ophthalmology-and-Optometry-Macular-Degeneration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life Science Analytics, ... information on the current drug pipeline. This ...
Cached Medicine News:Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 2Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 3Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 3Health News:Stroke Puts Stress on Spousal Relationship 2Health News:InVitria Reports Expanded Manufacturing Capability to Meet Commercial Demand for Lysobac, an Animal Free Reagent for Bacterial Fermentation 2Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 2Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 3Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 4Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 5Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 6Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 7Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 8Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 9Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 10Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 11Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 12Health News:Reportlinker Adds US World Nutraceutical Ingredients Industry 13Health News:Reportlinker Adds Ophthalmology and Optometry Macular Degeneration 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: